^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Hematological Malignancies

    Related cancers:
    21h
    Interaction between HIV-1 Tat and EBV Zta favours immune escape of B cells by downregulating HLA-ABC expression. (PubMed, Cell Mol Life Sci)
    To conclude, we demonstrated for the first time that HIV-1 Tat and EBV Zta interacted directly in B cells and blood serum; this interaction can be found in people with HIV. This interaction brings about immune evasion of EBV-infected or transformed B cells.
    Journal
    |
    HLA-C (Major Histocompatibility Complex, Class I, C)
    21h
    MEXIRON: Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or Myelofibrosis (clinicaltrials.gov)
    P=N/A, N=13, Recruiting, Hospices Civils de Lyon | Trial completion date: Oct 2026 --> May 2027 | Trial primary completion date: Jul 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    21h
    Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2026 --> Feb 2028 | Trial primary completion date: Feb 2026 --> Feb 2028
    Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • KMT2D (Lysine Methyltransferase 2D) • NOTCH2 (Notch 2) • BIRC3 (Baculoviral IAP repeat containing 3) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2)
    |
    TP53 mutation • CD20 positive • TP53 wild-type
    |
    Imbruvica (ibrutinib)
    21h
    Motixafortide for MRD Sensitization in AML (clinicaltrials.gov)
    P2, N=10, Not yet recruiting, Washington University School of Medicine
    New P2 trial
    |
    Aphexda (motixafortide)
    22h
    PEPN22P1: Vincristine Pharmacokinetics in Infants (clinicaltrials.gov)
    P=N/A, N=83, Active, not recruiting, Children's Oncology Group | Trial completion date: Dec 2025 --> Sep 2026 | Trial primary completion date: Dec 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    vincristine
    22h
    DURGA-4: A Phase III, Open-label, Randomised, Multicentre Study to Evaluate AZD0120 in Participants With Relapsed Refractory Multiple Myeloma. (clinicaltrials.gov)
    P3, N=508, Not yet recruiting, AstraZeneca
    New P3 trial
    |
    bortezomib • Darzalex (daratumumab) • carfilzomib • dexamethasone • pomalidomide • AZD0120
    23h
    NCI-2018-00410: Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations (clinicaltrials.gov)
    P2, N=28, Active, not recruiting, Ohio State University Comprehensive Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib)
    23h
    Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) (clinicaltrials.gov)
    P2, N=160, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2026 --> Feb 2028 | Trial primary completion date: Feb 2026 --> Feb 2028
    Trial completion date • Trial primary completion date
    |
    cytarabine • decitabine • cladribine • Depocyte (liposomal cytarabine)
    24h
    ZLPM-004-1.0: A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, Chengdu Zenitar Biomedical Technology Co., Ltd | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Nov 2025 --> Jun 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    purinostat
    1d
    DoMMino-1: Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=100, Recruiting, CellCentric Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    dexamethasone • pomalidomide • inobrodib (CCS1477)
    1d
    A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) (clinicaltrials.gov)
    P2, N=87, Completed, Eli Lilly and Company | Active, not recruiting --> Completed
    Trial completion
    |
    Jaypirca (pirtobrutinib)
    1d
    PEACE: Pediatric Early Rehabilitation in Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P=N/A, N=10, Completed, University of Alberta | Recruiting --> Completed
    Trial completion